Omeros' OMS302 meets Phase III endpoints

Omeros Corp. (NASDAQ:OMER) said OMS302 met the co-primary endpoints in a Phase III trial to maintain pupil dilation during cataract and other lens replacement surgery. Specifically, OMS302 plus standard irrigation solution used during ophthalmological procedures significantly improved maintenance of intraoperative pupil dilation (p<0.00001) and reduced pain in the early post-operative period (p=0.0002) vs. placebo. The double-blind, international Phase III trial enrolled 416 patients undergoing intraocular lens replacement surgery.

In March, Omeros reported data from a double-blind, U.S. Phase III trial in 405 patients undergoing lens replacement surgery showing that OMS302 met the primary endpoint of superior maintenance of intraoperative pupil dilation vs. placebo (p<0.00001) (see BioCentury Extra, March 13). ...